SCHEMBL25627230

SCHEMBL25627230

Cn1ccc2cc(C(C)(C)C)c(CN3CCNCC3)nc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 1/20 0.36
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ CXCR4 P61073 5/20 0.34
▸ SIGMAR1 Q99720 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ SOS1 Q07889 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ CHRM2 P08172 1/20 0.32
▸ CHRM1 P11229 1/20 0.32
▸ ADRA2C P18825 1/20 0.32
▸ CCR2 P41597 1/20 0.32
▸ CXCL12 P48061 1/20 0.32
▸ BLM P54132 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ HRH3 Q9Y5N1 1/20 0.32
▸ HTR6 P50406 3/20 0.32
▸ TRPV4 Q9HBA0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13824599 0.77 — —
SCHEMBL25613158 0.76 MAP3K11 (0.36) HRH4MEN1KMT2ACXCR4SIGMAR1
SCHEMBL25627937 0.72 CNR2 (0.30) —
SCHEMBL11915974 0.66 SIGMAR1 (0.37) MEN1KMT2ACXCR4SIGMAR1ALDH1A1
SCHEMBL25613148 0.65 KDM4E (0.38) SIGMAR1ALDH1A1KDM4EMAPTTDP1
SCHEMBL25613161 0.65 KDM4E (0.40) SIGMAR1ALDH1A1KDM4EMAPTTDP1
SCHEMBL17955426 0.64 LMNA (0.61) KMT2ASIGMAR1ALDH1A1LMNAKDM4E
SCHEMBL25613160 0.62 ALOX15 (0.41) MEN1KMT2ACXCR4ALDH1A1LMNA
SCHEMBL7093421 0.62 ALDH1A1 (0.71) MEN1KMT2ACXCR4SIGMAR1ALDH1A1
SCHEMBL20224113 0.62 CXCR4 (0.46) MEN1KMT2ACXCR4SIGMAR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 HRH4 4874/4885MEN1 4012/4885KMT2A 2209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback